Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Mineralys Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.48, Mineralys Therapeutics, Inc. trades at 2.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -63.3%, return on invested capital of -64.7% and a free cash flow yield of -11.9%. On the balance sheet: a debt-to-equity ratio of 0.20 and a current ratio of 11.83. Over the past 52 weeks the share price ranged from $14.30 to $45.00, with a beta of 0.69.
Mineralys Therapeutics, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 7 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.